
Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter. In Q4, Editas Medicine brought in $12.47 million in sales but lost $41.44 million in earnings.